Login Register Cart 0
Review Article

糖酵解抑制剂对肿瘤放射致敏过程中免疫生物组的调节

卷 27, 期 24, 2020

页: [4002 - 4015] 页: 14

弟呕挨: 10.2174/0929867325666180601101145

价格: $65

摘要

包括基质细胞，成纤维细胞和免疫系统各种成分的肿瘤微环境（TME）在肿瘤细胞周围形成促肿瘤原性茧，并以肿瘤中的Warburg表型（增强的需氧糖酵解）形式重新编程新陈代谢。非肿瘤细胞。该重编程在抑制导致肿瘤细胞存活和增殖以及对治疗的抗性的免疫应答中起重要作用。因此，除增强对肿瘤细胞的直接作用外，对开发涉及代谢修饰剂以改善恢复免疫能力的治疗功效的策略有相当大的兴趣。糖酵解抑制剂如2-脱氧-D-葡萄糖（2-DG；己糖激酶抑制剂），二氯乙酸盐和乳酸盐转运的小分子抑制剂（MCT-1）是研究其治疗和佐剂潜力的代谢修饰剂。其中，2-DG已被广泛研究并确立为肿瘤放疗和化疗的理想佐剂。以细胞因子转移，差异转录调节，免疫抑制网络的废除和乳酸积累减少等形式对免疫生物组的调节是与糖酵解抑制剂的放射增敏和化学增敏相关的免疫刺激的一些促成因素。

关键词: 糖酵解，代谢修饰剂，2-DG，免疫调节，放射增敏，免疫抑制，免疫刺激。

« Previous Next »
[1]
Terme, M.; Ullrich, E.; Aymeric, L.; Meinhardt, K.; Coudert, J.D.; Desbois, M.; Ghiringhelli, F.; Viaud, S.; Ryffel, B.; Yagita, H.; Chen, L.; Mécheri, S.; Kaplanski, G.; PrévostBlondel, A.; Kato, M.; Schultze, J.L.; Tartour, E.; Kroemer, G.; Degli-Esposti, M.; Chaput, N.; Zitvogel, L. Cancer induced immunosuppression: IL-18-elicited immunoablative NK cells. Cancer Res., 2012, 72(11), 2757-2767.
[http://dx.doi.org/10.1158/0008-5472.CAN-11-3379] [PMID: 22427351]
[2]
Messerschmidt, J.L.; Bhattacharya, P.; Messerschmidt, G.L. Cancer clonal theory, immune escape, and their evolving roles in cancer multi-agent therapeutics. Curr. Oncol. Rep., 2017, 19(10), 66.
[http://dx.doi.org/10.1007/s11912-017-0625-2] [PMID: 28803390]
[3]
Galluzzi, L.; Zitvogel, L.; Kroemer, G. Immunological mechanisms underneath the efficacy of cancer therapy. Cancer Immunol. Res., 2016, 4(11), 895-902.
[http://dx.doi.org/10.1158/2326-6066.CIR-16-0197] [PMID: 27803050]
[4]
Ma, Y.; Kepp, O.; Ghiringhelli, F.; Apetoh, L.; Aymeric, L.; Locher, C.; Tesniere, A.; Martins, I.; Ly, A.; Haynes, N.M.; Smyth, M.J.; Kroemer, G.; Zitvogel, L. Chemotherapy and radiotherapy: cryptic anticancer vaccines. Semin. Immunol., 2010, 22(3), 113-124.
[http://dx.doi.org/10.1016/j.smim.2010.03.001] [PMID: 20403709]
[5]
Shurin, M.R.; Naiditch, H.; Gutkin, D.W.; Umansky, V.; Shurin, G.V. ChemoImmunoModulation: immune regulation by the antineoplastic chemotherapeutic agents. Curr. Med. Chem., 2012, 19(12), 1792-1803.
[http://dx.doi.org/10.2174/092986712800099785] [PMID: 22414087]
[6]
Sukumar, M.; Roychoudhuri, R.; Restifo, N.P. Nutrient competition: a new axis of tumor immunosuppression. Cell, 2015, 162(6), 1206-1208.
[http://dx.doi.org/10.1016/j.cell.2015.08.064] [PMID: 26359979]
[7]
Zitvogel, L.; Apetoh, L.; Ghiringhelli, F.; André, F.; Tesniere, A.; Kroemer, G. The anticancer immune response: indispensable for therapeutic success? J. Clin. Invest., 2008, 118(6), 1991-2001.
[http://dx.doi.org/10.1172/JCI35180] [PMID: 18523649]
[8]
Farooque, A.; Singh, N.; Adhikari, J.S.; Afrin, F.; Dwarakanath, B.S. Enhanced antitumor immunity contributes to the radio-sensitization of ehrlich ascites tumor by the glycolytic inhibitor 2-deoxy-D-glucose in mice. PLoS One, 2014, 9(9),e108131.
[http://dx.doi.org/10.1371/journal.pone.0108131] [PMID: 25248151]
[9]
Farooque, A.; Afrin, F.; Adhikari, J.S.; Dwarakanath, B.S. Polarization of macrophages towards M1 phenotype by a combination of 2-deoxy-d-glucose and radiation: Implications for tumor therapy. Immunobiology, 2016, 221(2), 269-281.
[http://dx.doi.org/10.1016/j.imbio.2015.10.009] [PMID: 26597503]
[10]
Dwarakanath, B.S.; Singh, S.; Jain, V. Optimization of tumour radiotherapy: Part V--Radiosensitization by 2-deoxyD-glucose and DNA ligand Hoechst-33342 in a murine tumour. Indian J. Exp. Biol., 1999, 37(9), 865-870.
[PMID: 10687280]
[11]
Gupta, S.; Farooque, A.; Adhikari, J.S.; Singh, S.; Dwarakanath, B.S. Enhancement of radiation and chemotherapeutic drug responses by 2-deoxyD-glucose in animal tumors. J. Cancer Res. Ther., 2009, 5(Suppl. 1), S16-S20.
[http://dx.doi.org/10.4103/0973-1482.55135] [PMID: 20009287]
[12]
Farooque, A.; Afrin, F.; Adhikari, J.S.; Dwarakanath, B.S. Protection of normal cells and tissues during radio- and chemosensitization of tumors by 2-deoxy-D-glucose. J. Cancer Res. Ther., 2009, 5(Suppl. 1), S32-S35.
[http://dx.doi.org/10.4103/0973-1482.55138] [PMID: 20009291]
[13]
Dwarakanath, B.S. Cytotoxicity, radiosensitization, and chemosensitization of tumor cells by 2-deoxy-D-glucose in vitro. J. Cancer Res. Ther., 2009, 5(Suppl. 1), S27-S31.
[http://dx.doi.org/10.4103/0973-1482.55137] [PMID: 20009290]
[14]
Jain, V. Modifications of radiation responses by 2-deoxy-D-glucose in normal and cancer cells. Indian J. Nucl. Med., 1996, 11, 8-17.
[15]
Chen, K.; Xu, X.; Kobayashi, S.; Timm, D.; Jepperson, T.; Liang, Q. Caloric restriction mimetic 2-deoxyglucose antagonizes doxorubicin-induced cardiomyocyte death by multiple mechanisms. J. Biol. Chem., 2011, 286(25), 21993-22006.
[http://dx.doi.org/10.1074/jbc.M111.225805] [PMID: 21521688]
[16]
Singh, S.; Pandey, S.; Bhatt, A.N.; Chaudhary, R.; Bhuria, V.; Kalra, N.; Soni, R.; Roy, B.G.; Saluja, D.; Dwarakanath, B.S. Chronic dietary administration of the glycolytic inhibitor 2-Deoxy-D-Glucose (2-DG) inhibits the growth of implanted ehrlich’s ascites tumor in mice. PLoS One, 2015, 10(7),e0132089.
[http://dx.doi.org/10.1371/journal.pone.0132089] [PMID: 26135741]
[17]
Ohashi, T.; Akazawa, T.; Aoki, M.; Kuze, B.; Mizuta, K.; Ito, Y.; Inoue, N. Dichloroacetate improves immune dysfunction caused by tumor-secreted lactic acid and increases antitumor immunoreactivity. Int. J. Cancer, 2013, 133(5), 1107-1118.
[http://dx.doi.org/10.1002/ijc.28114] [PMID: 23420584]
[18]
Gupta, S.; Roy, A.; Dwarakanath, B.S. Metabolic cooperation and competition in the tumor microenvironment: implications for therapy. Front. Oncol., 2017, 7, 68.
[http://dx.doi.org/10.3389/fonc.2017.00068] [PMID: 28447025]
[19]
Pietras, K.; Ostman, A. Hallmarks of cancer: interactions with the tumor stroma. Exp. Cell Res., 2010, 316(8), 1324-1331.
[http://dx.doi.org/10.1016/j.yexcr.2010.02.045] [PMID: 20211171]
[20]
Kalluri, R.; Zeisberg, M. Fibroblasts in cancer. Nat. Rev. Cancer, 2006, 6(5), 392-401.
[http://dx.doi.org/10.1038/nrc1877] [PMID: 16572188]
[21]
Amatangelo, M.D.; Bassi, D.E.; Klein-Szanto, A.J.; Cukierman, E. Stroma-derived three-dimensional matrices are necessary and sufficient to promote desmoplastic differentiation of normal fibroblasts. Am. J. Pathol., 2005, 167(2), 475-488.
[http://dx.doi.org/10.1016/S0002-9440(10)62991-4] [PMID: 16049333]
[22]
Martinez-Outschoorn, U.; Sotgia, F.; Lisanti, M.P. Tumor microenvironment and metabolic synergy in breast cancers: critical importance of mitochondrial fuels and function. Semin. Oncol., 2014, 41(2), 195-216.
[http://dx.doi.org/10.1053/j.seminoncol.2014.03.002] [PMID: 24787293]
[23]
Choi, S.Y.; Collins, C.C.; Gout, P.W.; Wang, Y. Cancer generated lactic acid: a regulatory, immunosuppressive metabolite? J. Pathol., 2013, 230(4), 350-355.
[http://dx.doi.org/10.1002/path.4218] [PMID: 23729358]
[24]
Siemann, D.W. The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by tumor-vascular disrupting agents. Cancer Treat. Rev., 2011, 37(1), 63-74.
[http://dx.doi.org/10.1016/j.ctrv.2010.05.001] [PMID: 20570444]
[25]
Nagy, J.A.; Chang, S.H.; Dvorak, A.M.; Dvorak, H.F. Why are tumour blood vessels abnormal and why is it important to know? Br. J. Cancer, 2009, 100(6), 865-869.
[http://dx.doi.org/10.1038/sj.bjc.6604929] [PMID: 19240721]
[26]
Chiche, J.; Brahimi-Horn, M.C.; Pouysségur, J. Tumour hypoxia induces a metabolic shift causing acidosis: a common feature in cancer. J. Cell. Mol. Med., 2010, 14(4), 771-794.
[http://dx.doi.org/10.1111/j.1582-4934.2009.00994.x] [PMID: 20015196]
[27]
Peppicelli, S.; Ruzzolini, E.A.J.; Margheri, F.; Laurenzana, A.; Bianchini, F.; Calorini, L. Acidity of microenvironment as a further driver of tumor metabolic reprogramming. J. Clin. Cell. Immunol., 2017, 8(1), 485-489.
[http://dx.doi.org/10.4172/2155-9899.1000485]
[28]
Justus, C.R.; Sanderlin, E.J.; Yang, L.V. Molecular connections between cancer cell metabolism and the tumor microenvironment. Int. J. Mol. Sci., 2015, 16(5), 11055-11086.
[http://dx.doi.org/10.3390/ijms160511055] [PMID: 25988385]
[29]
Chen, J.L.; Lucas, J.E.; Schroeder, T.; Mori, S.; Wu, J.; Nevins, J.; Dewhirst, M.; West, M.; Chi, J.T. The genomic analysis of lactic acidosis and acidosis response in human cancers. PLoS Genet., 2008, 4(12),e1000293.
[http://dx.doi.org/10.1371/journal.pgen.1000293] [PMID: 19057672]
[30]
Xie, J.; Wu, H.; Dai, C.; Pan, Q.; Ding, Z.; Hu, D.; Ji, B.; Luo, Y.; Hu, X. Beyond Warburg effect--dual metabolic nature of cancer cells. Sci. Rep., 2014, 4, 4927.
[http://dx.doi.org/10.1038/srep04927] [PMID: 24820099]
[31]
Husain, Z.; Seth, P.; Sukhatme, V.P. Tumor-derived lactate and myeloid-derived suppressor cells: Linking metabolism to cancer immunology. OncoImmunology, 2013, 2(11),e26383.
[http://dx.doi.org/10.4161/onci.26383] [PMID: 24404426]
[32]
Brand, A.; Singer, K.; Koehl, G.E.; Kolitzus, M.; Schoenhammer, G.; Thiel, A.; Matos, C.; Bruss, C.; Klobuch, S.; Peter, K.; Kastenberger, M.; Bogdan, C.; Schleicher, U.; Mackensen, A.; Ullrich, E.; Fichtner-Feigl, S.; Kesselring, R.; Mack, M.; Ritter, U.; Schmid, M.; Blank, C.; Dettmer, K.; Oefner, P.J.; Hoffmann, P.; Walenta, S.; Geissler, E.K.; Pouyssegur, J.; Villunger, A.; Steven, A.; Seliger, B.; Schreml, S.; Haferkamp, S.; Kohl, E.; Karrer, S.; Berneburg, M.; Herr, W.; Mueller-Klieser, W.; Renner, K.; Kreutz, M. LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK Cells. Cell Metab., 2016, 24(5), 657-671.
[http://dx.doi.org/10.1016/j.cmet.2016.08.011] [PMID: 27641098]
[33]
Lawless, S.J.; Kedia-Mehta, N.; Walls, J.F.; McGarrigle, R.; Convery, O.; Sinclair, L.V.; Navarro, M.N.; Murray, J.; Finlay, D.K. Glucose represses dendritic cell-induced T cell responses. Nat. Commun., 2017, 8, 15620.
[http://dx.doi.org/10.1038/ncomms15620] [PMID: 28555668]
[34]
Pearce, E.L.; Pearce, E.J. Metabolic pathways in immune cell activation and quiescence. Immunity, 2013, 38(4), 633-643.
[http://dx.doi.org/10.1016/j.immuni.2013.04.005] [PMID: 23601682]
[35]
Ward, P.S.; Thompson, C.B. Signaling in control of cell growth and metabolism. Cold Spring Harb. Perspect. Biol., 2012, 4(7),a006783.
[http://dx.doi.org/10.1101/cshperspect.a006783] [PMID: 22687276]
[36]
Bronte, V.; Pittet, M.J. The spleen in local and systemic regulation of immunity. Immunity, 2013, 39(5), 806-818.
[http://dx.doi.org/10.1016/j.immuni.2013.10.010] [PMID: 24238338]
[37]
Cortez-Retamozo, V.; Etzrodt, M.; Newton, A.; Rauch, P.J.; Chudnovskiy, A.; Berger, C.; Ryan, R.J.; Iwamoto, Y.; Marinelli, B.; Gorbatov, R.; Forghani, R.; Novobrantseva, T.I.; Koteliansky, V.; Figueiredo, J.L.; Chen, J.W.; Anderson, D.G.; Nahrendorf, M.; Swirski, F.K.; Weissleder, R.; Pittet, M.J. Origins of tumor-associated macrophages and neutrophils. Proc. Natl. Acad. Sci. USA, 2012, 109(7), 2491-2496.
[http://dx.doi.org/10.1073/pnas.1113744109] [PMID: 22308361]
[38]
Qian, B.Z.; Pollard, J.W. Macrophage diversity enhances tumor progression and metastasis. Cell, 2010, 141(1), 39-51.
[http://dx.doi.org/10.1016/j.cell.2010.03.014] [PMID: 20371344]
[39]
Maier, P.; Hartmann, L.; Wenz, F.; Herskind, C. Cellular pathways in response to ionizing radiation and their targetability for tumor radiosensitization. Int. J. Mol. Sci., 2016, 17(1),E102.
[http://dx.doi.org/10.3390/ijms17010102] [PMID: 26784176]
[40]
Rubner, Y.; Wunderlich, R.; Rühle, P.F.; Kulzer, L.; Werthmöller, N.; Frey, B.; Weiss, E.M.; Keilholz, L.; Fietkau, R.; Gaipl, U.S. How does ionizing irradiation contribute to the induction of anti-tumor immunity? Front. Oncol., 2012, 2, 75.
[http://dx.doi.org/10.3389/fonc.2012.00075] [PMID: 22848871]
[41]
Farooque, A.; Mathur, R.; Verma, A.; Kaul, V.; Bhatt, A.N.; Adhikari, J.S.; Afrin, F.; Singh, S.; Dwarakanath, B.S. Low dose radiation therapy of cancer: role of immune enhancement. Expert Rev. Anticancer Ther., 2011, 11(5), 791-802.
[http://dx.doi.org/10.1586/era.10.217] [PMID: 21554054]
[42]
Ahmed, M.M.; Hodge, J.W.; Guha, C.; Bernhard, E.J.; Vikram, B.; Coleman, C.N. Harnessing the potential of radiation-induced immune modulation for cancer therapy. Cancer Immunol. Res., 2013, 1(5), 280-284.
[http://dx.doi.org/10.1158/2326-6066.CIR-13-0141] [PMID: 24777964]
[43]
Kasid, U.; Suy, S.; Dent, P.; Ray, S.; Whiteside, T.L.; Sturgill, T.W. Activation of Raf by ionizing radiation. Nature, 1996, 382(6594), 813-816.
[http://dx.doi.org/10.1038/382813a0] [PMID: 8752275]
[44]
Lander, H.M.; Tauras, J.M.; Ogiste, J.S.; Hori, O.; Moss, R.A.; Schmidt, A.M. Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J. Biol. Chem., 1997, 272(28), 17810-17814.
[http://dx.doi.org/10.1074/jbc.272.28.17810] [PMID: 9211935]
[45]
Finkel, T. Oxygen radicals and signaling. Curr. Opin. Cell Biol., 1998, 10(2), 248-253.
[http://dx.doi.org/10.1016/S0955-0674(98)80147-6] [PMID: 9561849]
[46]
Rho, H.S.; Park, S.S.; Lee, C.E. Gamma irradiation up-regulates expression of B cell differentiation molecule CD23 by NF-kappaB activation. J. Biochem. Mol. Biol., 2004, 37(4), 507-514.
[PMID: 15469741]
[47]
Shan, Y.X.; Jin, S.Z.; Liu, X.D.; Liu, Y.; Liu, S.Z. Ionizing radiation stimulates secretion of pro-inflammatory cytokines: dose-response relationship, mechanisms and implications. Radiat. Environ. Biophys., 2007, 46(1), 21-29.
[http://dx.doi.org/10.1007/s00411-006-0076-x] [PMID: 17072632]
[48]
Shankar, B.; Premachandran, S.; Bharambe, S.D.; Sundaresan, P.; Sainis, K.B. Modification of immune response by low dose ionizing radiation: role of apoptosis. Immunol. Lett., 1999, 68(2-3), 237-245.
[http://dx.doi.org/10.1016/S0165-2478(99)00074-7] [PMID: 10424426]
[49]
Villar, R.C. Radiotherapy and immunity- a mini review in: Immunosuppression- Role in Health and Diseases; Kapur, D.S., Ed.; InTech, 2012.
[50]
Lumniczky, K.; Sáfrány, G. The impact of radiation therapy on the antitumor immunity: local effects and systemic consequences. Cancer Lett., 2015, 356(1), 114-125.
[http://dx.doi.org/10.1016/j.canlet.2013.08.024] [PMID: 23994343]
[51]
Siva, S.; MacManus, M.; Kron, T.; Best, N.; Smith, J.; Lobachevsky, P.; Ball, D.; Martin, O. A pattern of early radiation-induced inflammatory cytokine expression is associated with lung toxicity in patients with non-small cell lung cancer. PLoS One, 2014, 9(10)e109560
[http://dx.doi.org/10.1371/journal.pone.0109560] [PMID: 25289758]
[52]
Pandey, S.; Singh, S.; Anang, V.; Bhatt, A.N.; Natarajan, K.; Dwarakanath, B.S. Pattern recognition receptors in cancer progression and metastasis. Cancer Growth Metastasis, 2015, 8, 25-34.
[http://dx.doi.org/10.4137/CGM.S24314] [PMID: 26279628]
[53]
Schaue, D.; McBride, W.H. Links between innate immunity and normal tissue radiobiology. Radiat. Res., 2010, 173(4), 406-417.
[http://dx.doi.org/10.1667/RR1931.1] [PMID: 20334512]
[54]
Apetoh, L.; Ghiringhelli, F.; Tesniere, A.; Obeid, M.; Ortiz, C.; Criollo, A.; Mignot, G.; Maiuri, M.C.; Ullrich, E.; Saulnier, P.; Yang, H.; Amigorena, S.; Ryffel, B.; Barrat, F.J.; Saftig, P.; Levi, F.; Lidereau, R.; Nogues, C.; Mira, J.P.; Chompret, A.; Joulin, V.; Clavel-Chapelon, F.; Bourhis, J.; André, F.; Delaloge, S.; Tursz, T.; Kroemer, G.; Zitvogel, L. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med., 2007, 13(9), 1050-1059.
[http://dx.doi.org/10.1038/nm1622] [PMID: 17704786]
[55]
Wei, S.; Egenti, M.U.; Teitz-Tennenbaum, S.; Zou, W.; Chang, A.E. Effects of tumor irradiation on host T-regulatory cells and systemic immunity in the context of adoptive T-cell therapy in mice. J. Immunother., 2013, 36(2), 124-132.
[http://dx.doi.org/10.1097/CJI.0b013e31828298e6] [PMID: 23377667]
[56]
Siva, S.; MacManus, M.P.; Martin, R.F.; Martin, O.A. Abscopal effects of radiation therapy: a clinical review for the radiobiologist. Cancer Lett., 2015, 356(1), 82-90.
[http://dx.doi.org/10.1016/j.canlet.2013.09.018] [PMID: 24125863]
[57]
Cameron, A.M.; Lawless, S.J.; Pearce, E.J. Metabolism and acetylation in innate immune cell function and fate. Semin. Immunol., 2016, 28(5), 408-416.
[http://dx.doi.org/10.1016/j.smim.2016.10.003] [PMID: 28340958]
[58]
Kelly, B.; O’Neill, L.A. Metabolic reprogramming in macrophages and dendritic cells in innate immunity. Cell Res., 2015, 25(7), 771-784.
[http://dx.doi.org/10.1038/cr.2015.68] [PMID: 26045163]
[59]
Galván-Peña, S.; O’Neill, L.A. Metabolic reprograming in macrophage polarization. Front. Immunol., 2014, 5, 420.
[PMID: 25228902]
[60]
Sun, J.C.; Lanier, L.L. Natural killer cells remember: an evolutionary bridge between innate and adaptive immunity? Eur. J. Immunol., 2009, 39(8), 2059-2064.
[http://dx.doi.org/10.1002/eji.200939435] [PMID: 19637199]
[61]
Terme, M.; Ullrich, E.; Delahaye, N.F.; Chaput, N.; Zitvogel, L. Natural killer cell-directed therapies: moving from unexpected results to successful strategies. Nat. Immunol., 2008, 9(5), 486-494.
[http://dx.doi.org/10.1038/ni1580] [PMID: 18425105]
[62]
Andresen, L.; Skovbakke, S.L.; Persson, G.; Hagemann-Jensen, M.; Hansen, K.A.; Jensen, H.; Skov, S. 2-deoxy D-glucose prevents cell surface expression of NKG2D ligands through inhibition of N-linked glycosylation. J. Immunol., 2012, 188(4), 1847-1855.
[http://dx.doi.org/10.4049/jimmunol.1004085] [PMID: 22227571]
[63]
Steinman, R.M. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol., 1991, 9, 271-296.
[http://dx.doi.org/10.1146/annurev.iy.09.040191.001415] [PMID: 1910679]
[64]
Stoitzner, P.; Green, L.K.; Jung, J.Y.; Price, K.M.; Atarea, H.; Kivell, B.; Ronchese, F. Inefficient presentation of tumor-derived antigen by tumor-infiltrating dendritic cells. Cancer Immunol. Immunother., 2008, 57(11), 1665-1673.
[http://dx.doi.org/10.1007/s00262-008-0487-4] [PMID: 18311487]
[65]
Ataera, H.; Hyde, E.; Price, K.M.; Stoitzner, P.; Ronchese, F. Murine melanoma-infiltrating dendritic cells are defective in antigen presenting function regardless of the presence of CD4CD25 regulatory T cells. PLoS One, 2011, 6(3)e17515
[http://dx.doi.org/10.1371/journal.pone.0017515] [PMID: 21390236]
[66]
Vesely, M.D.; Kershaw, M.H.; Schreiber, R.D.; Smyth, M.J. Natural innate and adaptive immunity to cancer. Annu. Rev. Immunol., 2011, 29, 235-271.
[http://dx.doi.org/10.1146/annurev-immunol-031210-101324] [PMID: 21219185]
[67]
de Visser, K.E.; Eichten, A.; Coussens, L.M. Paradoxical roles of the immune system during cancer development. Nat. Rev. Cancer, 2006, 6(1), 24-37.
[http://dx.doi.org/10.1038/nrc1782] [PMID: 16397525]
[68]
Kouidhi, S.; Noman, M.Z.; Kieda, C.; Elgaaied, A.B.; Chouaib, S. Intrinsic and tumor microenvironment-induced metabolism adaptations of T Cells and impact on their differentiation and function. Front. Immunol., 2016, 7, 114.
[http://dx.doi.org/10.3389/fimmu.2016.00114] [PMID: 27066006]
[69]
Buck, M.D.; O’Sullivan, D.; Pearce, E.L. T cell metabolism drives immunity. J. Exp. Med., 2015, 212(9), 1345-1360.
[http://dx.doi.org/10.1084/jem.20151159] [PMID: 26261266]
[70]
Jacobs, S.R.; Herman, C.E.; Maciver, N.J.; Wofford, J.A.; Wieman, H.L.; Hammen, J.J.; Rathmell, J.C. Glucose uptake is limiting in T cell activation and requires CD28-mediated Akt-dependent and independent pathways. J. Immunol., 2008, 180(7), 4476-4486.
[http://dx.doi.org/10.4049/jimmunol.180.7.4476] [PMID: 18354169]
[71]
Michalek, R.D.; Gerriets, V.A.; Jacobs, S.R.; Macintyre, A.N.; MacIver, N.J.; Mason, E.F.; Sullivan, S.A.; Nichols, A.G.; Rathmell, J.C. Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets. J. Immunol., 2011, 186(6), 3299-3303.
[http://dx.doi.org/10.4049/jimmunol.1003613] [PMID: 21317389]
[72]
Rubtsov, Y.P.; Niec, R.E.; Josefowicz, S.; Li, L.; Darce, J.; Mathis, D.; Benoist, C.; Rudensky, A.Y. Stability of the regulatory T cell lineage in vivo. Science, 2010, 329(5999), 1667-1671.
[http://dx.doi.org/10.1126/science.1191996] [PMID: 20929851]
[73]
van der Windt, G.J.; Everts, B.; Chang, C.H.; Curtis, J.D.; Freitas, T.C.; Amiel, E.; Pearce, E.J.; Pearce, E.L. Mitochondrial respiratory capacity is a critical regulator of CD8+ T cell memory development. Immunity, 2012, 36(1), 68-78.
[http://dx.doi.org/10.1016/j.immuni.2011.12.007] [PMID: 22206904]
[74]
Bénéteau, M.; Zunino, B.; Jacquin, M.A.; Meynet, O.; Chiche, J.; Pradelli, L.A.; Marchetti, S.; Cornille, A.; Carles, M.; Ricci, J.E. Combination of glycolysis inhibition with chemotherapy results in an antitumor immune response. Proc. Natl. Acad. Sci. USA, 2012, 109(49), 20071-20076.
[http://dx.doi.org/10.1073/pnas.1206360109] [PMID: 23169636]
[75]
Chen, M.L.; Pittet, M.J.; Gorelik, L.; Flavell, R.A.; Weissleder, R.; von Boehmer, H.; Khazaie, K. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. Proc. Natl. Acad. Sci. USA, 2005, 102(2), 419-424.
[http://dx.doi.org/10.1073/pnas.0408197102] [PMID: 15623559]
[76]
Chen, Y.; Sun, R.; Wu, X.; Cheng, M.; Wei, H.; Tian, Z. CD4+CD25+ regulatory T cells inhibit natural killer cell hepatocytotoxicity of hepatitis B virus transgenic mice via membrane-bound TGF-β and OX40. J. Innate Immun., 2016, 8(1), 30-42.
[http://dx.doi.org/10.1159/000431150] [PMID: 26067079]
[77]
Byrne, W.L.; Mills, K.H.; Lederer, J.A.; O’Sullivan, G.C. Targeting regulatory T cells in cancer. Cancer Res., 2011, 71(22), 6915-6920.
[http://dx.doi.org/10.1158/0008-5472.CAN-11-1156] [PMID: 22068034]
[78]
Kurtoglu, M.; Gao, N.; Shang, J.; Maher, J.C.; Lehrman, M.A.; Wangpaichitr, M.; Savaraj, N.; Lane, A.N.; Lampidis, T.J. Under normoxia, 2-deoxy-D-glucose elicits cell death in select tumor types not by inhibition of glycolysis but by interfering with N-linked glycosylation. Mol. Cancer Ther., 2007, 6(11), 3049-3058.
[http://dx.doi.org/10.1158/1535-7163.MCT-07-0310] [PMID: 18025288]
[79]
De Rosa, V.; Galgani, M.; Porcellini, A.; Colamatteo, A.; Santopaolo, M.; Zuchegna, C.; Romano, A.; De Simone, S.; Procaccini, C.; La Rocca, C.; Carrieri, P.B.; Maniscalco, G.T.; Salvetti, M.; Buscarinu, M.C.; Franzese, A.; Mozzillo, E.; La Cava, A.; Matarese, G. Glycolysis controls the induction of human regulatory T cells by modulating the expression of FOXP3 exon 2 splicing variants. Nat. Immunol., 2015, 16(11), 1174-1184.
[http://dx.doi.org/10.1038/ni.3269] [PMID: 26414764]
[80]
Abdullah Farooque, A.V.; Niharika, Singh; Seema, Gupta in International conference on Radiation Biology (ICRB-2016) “High LET Radiation Biology and Complex Natural Products in Biology and Medicine"., Chennai, India,2016.
[81]
Nelson, B.H. CD20+ B cells: the other tumor-infiltrating lymphocytes. J. Immunol., 2010, 185(9), 4977-4982.
[http://dx.doi.org/10.4049/jimmunol.1001323] [PMID: 20962266]
[82]
Linnebacher, M.; Maletzki, C. Tumor-infiltrating B cells: The ignored players in tumor immunology. OncoImmunology, 2012, 1(7), 1186-1188.
[http://dx.doi.org/10.4161/onci.20641] [PMID: 23170274]
[83]
Caro-Maldonado, A.; Wang, R.; Nichols, A.G.; Kuraoka, M.; Milasta, S.; Sun, L.D.; Gavin, A.L.; Abel, E.D.; Kelsoe, G.; Green, D.R.; Rathmell, J.C. Metabolic reprogramming is required for antibody production that is suppressed in anergic but exaggerated in chronically BAFF-exposed B cells. J. Immunol., 2014, 192(8), 3626-3636.
[http://dx.doi.org/10.4049/jimmunol.1302062] [PMID: 24616478]
[84]
Parker, D.C. T cell-dependent B cell activation. Annu. Rev. Immunol., 1993, 11, 331-360.
[http://dx.doi.org/10.1146/annurev.iy.11.040193.001555] [PMID: 8476565]
[85]
Vitetta, E.S.; Fernandez-Botran, R.; Myers, C.D.; Sanders, V.M. Cellular interactions in the humoral immune response. Adv. Immunol., 1989, 45, 1-105.
[http://dx.doi.org/10.1016/S0065-2776(08)60692-6] [PMID: 2665437]
[86]
Phillips, M.M.; Sheaff, M.T.; Szlosarek, P.W. Targeting arginine-dependent cancers with arginine-degrading enzymes: opportunities and challenges. Cancer Res. Treat., 2013, 45(4), 251-262.
[http://dx.doi.org/10.4143/crt.2013.45.4.251] [PMID: 24453997]
[87]
Rodriguez, P.C.; Quiceno, D.G.; Zabaleta, J.; Ortiz, B.; Zea, A.H.; Piazuelo, M.B.; Delgado, A.; Correa, P.; Brayer, J.; Sotomayor, E.M.; Antonia, S.; Ochoa, J.B.; Ochoa, A.C. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res., 2004, 64(16), 5839-5849.
[http://dx.doi.org/10.1158/0008-5472.CAN-04-0465] [PMID: 15313928]
[88]
Srivastava, M.K.; Sinha, P.; Clements, V.K.; Rodriguez, P.; Ostrand-Rosenberg, S. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res., 2010, 70(1), 68-77.
[http://dx.doi.org/10.1158/0008-5472.CAN-09-2587] [PMID: 20028852]
[89]
Abdullah Farooque, F.A.; ; Jawahar, Singh,; Adhikari, ; Dwarakanath.,, B.S. 8th Annual Meeting of the Cytometry Society and the 16th Indo-US Cytometry Workshop. Tata Memorial Centre, Mumbai, India, 2015.
[90]
Gandhi, S.; Chandna, S. Radiation-induced inflammatory cascade and its reverberating crosstalks as potential cause of post-radiotherapy second malignancies. Cancer Metastasis Rev., 2017, 36(2), 375-393.
[http://dx.doi.org/10.1007/s10555-017-9669-x] [PMID: 28707199]
[91]
Multhoff, G.; Radons, J. Radiation, inflammation, and immune responses in cancer. Front. Oncol., 2012, 2, 58.
[http://dx.doi.org/10.3389/fonc.2012.00058] [PMID: 22675673]
[92]
Wang, H.; Wang, L.; Zhang, Y.; Wang, J.; Deng, Y.; Lin, D. Inhibition of glycolytic enzyme hexokinase II (HK2) suppresses lung tumor growth. Cancer Cell Int., 2016, 16, 9.
[http://dx.doi.org/10.1186/s12935-016-0280-y] [PMID: 26884725]
[93]
Botzer, L.E.; Maman, S.; Sagi-Assif, O.; Meshel, T.; Nevo, I.; Yron, I.; Witz, I.P. Hexokinase 2 is a determinant of neuroblastoma metastasis. Br. J. Cancer, 2016, 114(7), 759-766.
[http://dx.doi.org/10.1038/bjc.2016.26] [PMID: 26986252]
[94]
Brown, J. Effects of 2-deoxyglucose on carbohydrate metablism: review of the literature and studies in the rat. Metabolism, 1962, 11, 1098-1112.
[PMID: 13873661]
[95]
McComb, R.B.; Yushok, W.D. Metabolism of ascites tumor cells. iv. enzymatic reactions involved in adenosinetriphosphate degradation induced by 2-deoxyglucose. Cancer Res., 1964, 24, 198-205.
[PMID: 14115684]
[96]
Sharma, P.K.; Dwarakanath, B.S.; Varshney, R. Radiosensitization by 2-deoxy-D-glucose and 6-aminonicotinamide involves activation of redox sensitive ASK1-JNK/p38MAPK signaling in head and neck cancer cells. Free Radic. Biol. Med., 2012, 53(7), 1500-1513.
[http://dx.doi.org/10.1016/j.freeradbiomed.2012.07.001] [PMID: 22824861]
[97]
Varshney, R.; Dwarakanath, B.; Jain, V. Radiosensitization by 6-aminonicotinamide and 2-deoxy-D-glucose in human cancer cells. Int. J. Radiat. Biol., 2005, 81(5), 397-408.
[http://dx.doi.org/10.1080/09553000500148590] [PMID: 16076755]
[98]
Varshney, R.; Gupta, S.; Dwarakanath, B.S. Radiosensitization of murine Ehrlich ascites tumor by a combination of 2-deoxy-D-glucose and 6-aminonicotinamide. Technol. Cancer Res. Treat., 2004, 3(6), 659-663.
[http://dx.doi.org/10.1177/153303460400300616] [PMID: 15560724]
[99]
Mohanti, B.K.; Rath, G.K.; Anantha, N.; Kannan, V.; Das, B.S.; Chandramouli, B.A.; Banerjee, A.K.; Das, S.; Jena, A.; Ravichandran, R.; Sahi, U.P.; Kumar, R.; Kapoor, N.; Kalia, V.K.; Dwarakanath, B.S.; Jain, V. Improving cancer radiotherapy with 2-deoxy-D-glucose: phase I/II clinical trials on human cerebral gliomas. Int. J. Radiat. Oncol. Biol. Phys., 1996, 35(1), 103-111.
[http://dx.doi.org/10.1016/S0360-3016(96)85017-6] [PMID: 8641905]
[100]
Singh, D.; Banerji, A.K.; Dwarakanath, B.S.; Tripathi, R.P.; Gupta, J.P.; Mathew, T.L.; Ravindranath, T.; Jain, V. Optimizing cancer radiotherapy with 2-deoxy-d-glucose dose escalation studies in patients with glioblastoma multiforme. Strahlenther. Onkol., 2005, 181(8), 507-514.
[http://dx.doi.org/10.1007/s00066-005-1320-z] [PMID: 16044218]
[101]
Dwarakanath, B.S.; Singh, D.; Banerji, A.K.; Sarin, R.; Venkataramana, N.K.; Jalali, R.; Vishwanath, P.N.; Mohanti, B.K.; Tripathi, R.P.; Kalia, V.K.; Jain, V. Clinical studies for improving radiotherapy with 2-deoxy-D-glucose: present status and future prospects. J. Cancer Res. Ther., 2009, 5(Suppl. 1), S21-S26.
[http://dx.doi.org/10.4103/0973-1482.55136] [PMID: 20009289]
[102]
Venkataramanaa, N.K.; Venkatesh, P.K.; Dwarakanath, B.S.; Vani, S. Protective effect on normal brain tissue during a combinational therapy of 2-deoxy-d-glucose and hypofractionated irradiation in malignant gliomas. Asian J. Neurosurg., 2013, 8(1), 9-14.
[http://dx.doi.org/10.4103/1793-5482.110274] [PMID: 23741257]
[103]
Strum, S.B.; Adalsteinsson, O.; Black, R.R.; Segal, D.; Peress, N.L.; Waldenfels, J. Case report: Sodium dichloroacetate (DCA) inhibition of the “Warburg Effect” in a human cancer patient: complete response in non-Hodgkin’s lymphoma after disease progression with rituximab-CHOP. J. Bioenerg. Biomembr., 2013, 45(3), 307-315.
[http://dx.doi.org/10.1007/s10863-012-9496-2] [PMID: 23263938]
[104]
Zhu, W.; Ye, L.; Zhang, J.; Yu, P.; Wang, H.; Ye, Z.; Tian, J. PFK15, a Small molecule inhibitor of PFKFB3, induces cell cycle arrest, apoptosis and inhibits invasion in gastric cancer. PLoS One, 2016, 11(9),e0163768
[http://dx.doi.org/10.1371/journal.pone.0163768] [PMID: 27669567]
[105]
Li, S.; Wu, L.; Feng, J.; Li, J.; Liu, T.; Zhang, R.; Xu, S.; Cheng, K.; Zhou, Y.; Zhou, S.; Kong, R.; Chen, K.; Wang, F.; Xia, Y.; Lu, J.; Zhou, Y.; Dai, W.; Guo, C. In vitro and in vivo study of epigallocatechin-3-gallate-induced apoptosis in aerobic glycolytic hepatocellular carcinoma cells involving inhibition of phosphofructokinase activity. Sci. Rep., 2016, 6, 28479.
[http://dx.doi.org/10.1038/srep28479] [PMID: 27349173]
[106]
Cantelmo, A.R.; Conradi, L.C.; Brajic, A.; Goveia, J.; Kalucka, J.; Pircher, A.; Chaturvedi, P.; Hol, J.; Thienpont, B.; Teuwen, L.A.; Schoors, S.; Boeckx, B.; Vriens, J.; Kuchnio, A.; Veys, K.; Cruys, B.; Finotto, L.; Treps, L.; Stav-Noraas, T.E.; Bifari, F.; Stapor, P.; Decimo, I.; Kampen, K.; De Bock, K.; Haraldsen, G.; Schoonjans, L.; Rabelink, T.; Eelen, G.; Ghesquière, B.; Rehman, J.; Lambrechts, D.; Malik, A.B.; Dewerchin, M.; Carmeliet, P. Inhibition of the glycolytic activator PFKFB3 in endothelium induces tumor vessel normalization, impairs metastasis, and improves chemotherapy. Cancer Cell, 2016, 30(6), 968-985.
[http://dx.doi.org/10.1016/j.ccell.2016.10.006] [PMID: 27866851]
[107]
Lian, N.; Jin, H.; Zhang, F.; Wu, L.; Shao, J.; Lu, Y.; Zheng, S. Curcumin inhibits aerobic glycolysis in hepatic stellate cells associated with activation of adenosine monophosphate-activated protein kinase. IUBMB Life, 2016, 68(7), 589-596.
[http://dx.doi.org/10.1002/iub.1518] [PMID: 27278959]
[108]
Majkowska-Skrobek, G.; Augustyniak, D.; Lis, P.; Bartkowiak, A.; Gonchar, M.; Ko, Y.H.; Pedersen, P.L.; Goffeau, A.; Ułaszewski, S. Killing multiple myeloma cells with the small molecule 3-bromopyruvate: implications for therapy. Anticancer Drugs, 2014, 25(6), 673-682.
[PMID: 24557015]
[109]
Papaldo, P.; Lopez, M.; Cortesi, E.; Cammilluzzi, E.; Antimi, M.; Terzoli, E.; Lepidini, G.; Vici, P.; Barone, C.; Ferretti, G.; Di Cosimo, S.; Nistico, C.; Carlini, P.; Conti, F.; Di Lauro, L.; Botti, C.; Vitucci, C.; Fabi, A.; Giannarelli, D.; Marolla, P. Addition of either lonidamine or granulocyte colony-stimulating factor does not improve survival in early breast cancer patients treated with high-dose epirubicin and cyclophosphamide. J. Clin. Oncol., 2003, 21(18), 3462-3468.
[http://dx.doi.org/10.1200/JCO.2003.03.034] [PMID: 12972521]
[110]
Di Cosimo, S.; Ferretti, G.; Papaldo, P.; Carlini, P.; Fabi, A.; Cognetti, F. Lonidamine: efficacy and safety in clinical trials for the treatment of solid tumors. Drugs Today (Barc), 2003, 39(3), 157-174.
[http://dx.doi.org/10.1358/dot.2003.39.3.799451] [PMID: 12730701]
[111]
Fang, J.; Quinones, Q.J.; Holman, T.L.; Morowitz, M.J.; Wang, Q.; Zhao, H.; Sivo, F.; Maris, J.M.; Wahl, M.L. The H+-linked monocarboxylate transporter (MCT1/SLC16A1): a potential therapeutic target for high-risk neuroblastoma. Mol. Pharmacol., 2006, 70(6), 2108-2115.
[http://dx.doi.org/10.1124/mol.106.026245] [PMID: 17000864]

Rights & Permissions Print Cite
Article Metrics
28
© 2024 Bentham Science Publishers | Privacy Policy